Lancet

Published by: Elsevier Science, Inc.  

People

  1. Motzer
    Motzer
  2. Bajorin
    Bajorin
  3. Rosenberg
    Rosenberg
  4. Scher
    Scher
  5. Abida
    Abida
  6. Danila
    Danila
  7. Fleisher
    Fleisher
  8. Humm
    Humm
  9. Morris
    Morris
  10. Rathkopf
    Rathkopf

Groups

  1. Department of Medicine (11)
  2. Genitourinary Oncology Service (11)
  3. Solid Tumor Oncology Division (11)
  4. Center for Hematologic Malignancies (1)
  5. Executive Committee, Center for Hematologic Malignancies (1)
  6. GSK Faculty (1)
  7. Hematologic Malignancies, Division of (1)
  8. Human Oncology and Pathogenesis Program (1)
  9. Medical Physics (1)
  10. Molecular Imaging and Therapy Service (1)
Search Within
  1. "Genitourinary Oncology Service"
Formats
  1. Journal Article (10)
  2. Editorial (1)
Groups
  1. Department of Medicine (11)
  2. Genitourinary Oncology Service (11)
  3. Solid Tumor Oncology Division (11)
  4. Center for Hematologic Malignancies (1)
  5. Executive Committee, Center for Hematologic Malignancies (1)
  6. GSK Faculty (1)

More Groups

People
  1. Robert Motzer (5)
  2. Dean Bajorin (2)
  3. Howard Scher (2)
  4. Jonathan Rosenberg (2)
  5. Aseem Anand (1)
  6. Charles Sawyers (1)

More People

Years
  1. 2023 (3)
  2. 2019 (1)
  3. 2017 (1)
  4. 2016 (2)
  5. 2011 (1)
  6. 2010 (1)

More Years

Publishers
  1. Elsevier Science, Inc. (11)

Results (11)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Combining next-generation hormonal therapy with PARP inhibition in metastatic castration-resistant prostate cancer
    Editorial

    Abida, W.; Attard, G.
    Lancet (2023)

    Fulltext@MSK | Save
  • Atezolizumab plus cabozantinib versus cabozantinib monotherapy for patients with renal cell carcinoma after progression with previous immune checkpoint inhibitor treatment (CONTACT-03): A multicentre, randomised, open-label, phase 3 trial
    Journal Article

    Pal, S. K.; Albiges, L.; Tomczak, P.; Suárez, C.; Voss, M. H.; de Velasco, G.; Chahoud, J.; Mochalova, A.; Procopio, G.; Mahammedi, H.; more...
    Lancet (2023)

    Fulltext@MSK | Save
  • Adjuvant nivolumab plus ipilimumab versus placebo for localised renal cell carcinoma after nephrectomy (CheckMate 914): A double-blind, randomised, phase 3 trial
    Journal Article

    Motzer, R. J.; Russo, P.; Grünwald, V.; Tomita, Y.; Zurawski, B.; Parikh, O.; Buti, S.; Barthélémy, P.; Goh, J. C.; Ye, D.; more...
    Lancet (2023)

    Fulltext@MSK | Save
  • Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): A multicentre, open-label, phase 3, randomised controlled trial
    Journal Article

    Rini, B. I.; Powles, T.; Atkins, M. B.; Escudier, B.; McDermott, D. F.; Suarez, C.; Bracarda, S.; Stadler, W. M.; Donskov, F.; Lee, J. L.; more...
    Lancet (2019)

    Fulltext@MSK | Save
  • Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: A single-arm, multicentre, phase 2 trial
    Journal Article

    Balar, A. V.; Galsky, M. D.; Rosenberg, J. E.; Powles, T.; Petrylak, D. P.; Bellmunt, J.; Loriot, Y.; Necchi, A.; Hoffman-Censits, J.; Perez-Gracia, J. L.; more...
    Lancet (2017)

    Fulltext@MSK | Save
  • Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: A single-arm, multicentre, phase 2 trial
    Journal Article

    Rosenberg, J. E.; Hoffman-Censits, J.; Powles, T.; van der Heijden, M. S.; Balar, A. V.; Necchi, A.; Dawson, N.; O'Donnell, P. H.; Balmanoukian, A.; Loriot, Y.; more...
    Lancet (2016)

    Fulltext@MSK | Save
  • Defining new standards of care for men with prostate cancer
    Journal Article

    Scher, H. I.
    Lancet (2016)

    Fulltext@MSK | Save
  • Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): A randomised phase 3 trial
    Journal Article

    Rini, B. I.; Escudier, B.; Tomczak, P.; Kaprin, A.; Szczylik, C.; Hutson, T. E.; Michaelson, M. D.; Gorbunova, V. A.; Gore, M. E.; Rusakov, I. G.; more...
    Lancet (2011)

    Fulltext@MSK | Save
  • Antitumour activity of MDV3100 in castration-resistant prostate cancer: A phase 1-2 study
    Journal Article

    Scher, H. I.; Anand, A.; Rathkopf, D.; Shelkey, J.; Morris, M. J.; Danila, D. C.; Larson, S.; Humm, J.; Fleisher, M.; Sawyers, C. L.; more...
    Lancet (2010)

    Fulltext@MSK | Save
  • Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial
    Journal Article

    Motzer, R. J.; Escudier, B.; Oudard, S.; Hutson, T. E.; Porta, C.; Bracarda, S.; Grünwald, V.; Thompson, J. A.; Figlin, R. A.; Hollaender, N.; more...
    Lancet (2008)

    Fulltext@MSK | Save

    • Lancet – authorized name for:

    Name ISSN / ISBN Publisher
    Lancet 0140-6736 Elsevier Science, Inc.
    Lancet 01406736 Unknown
    Lancet 0140-6736 Elsevier Science, Inc.
    Lancet 0140-6736 The Lancet Publishing Group
    Lancet 0140-6736 Elsevier Science, Inc.
    Lancet 0099-5355 The Lancet Publishing Group
    Lancet 1083-7159 Unknown
    Lancet 0099-5355 Unknown
    Lancet 0140-6736 Unknown
    Lancet 1474547X Unknown
    Lancet 1474-547X Elsevier Science, Inc.
    Lancet 0140-6736 Elsevier Science, Inc.
    Lancet 0140-6736 Elsevier Science, Inc.
    Lancet (North American Edition) 0140-6736 Unknown
    The Lancet 01406736 Elsevier Inc.
    The Lancet 0140-6736 Elsevier Science, Inc.
    The Lancet 01406736 1995
    The Lancet 1474547X Unknown
    The Lancet 01406736 Unknown
    The Lancet 01406736 1993
    The Lancet 0140-6736 Lancet United Kingdom
    The Lancet 01406736 1994
    The Lancet 01406736 Unknown
    The Lancet 0140-6736 Elsevier Inc.